• If you are looking at Halozyme Therapeutics and wondering whether the current share price reflects its true worth, this breakdown will help you make sense of what you are paying for.
• The stock recently closed at US$62.13, with returns of 1.2% decline over 7 days, 10.6% decline over 30 days, 11.6% decline year to date and 2.6% decline over 1 year, set against gains of 60.4% over 3 years and 44.7% over 5 years.
• Recent coverage has focused on how the share price has moved over different time frames and what that might say about changing expectations, with attention on both the shorter term pullback and the longer term gains. This context is useful because it frames the valuation question as investors weigh past returns against what the current price implies.
• On Simply Wall St's 6 point valuation checklist, Halozyme Therapeutics currently scores 3, with the full breakdown available in the valuation score. The next sections will walk through those standard valuation approaches before turning to a broader way of thinking about what the stock might be worth.

Approach 1: Halozyme Therapeutics Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. It is essentially asking what Halozyme Therapeutics’ future cash generation might be worth in today’s dollars.

Halozyme’s latest twelve month free cash flow is about $637.4 million. Using a 2 Stage Free Cash Flow to Equity model, Simply Wall St starts with analyst style estimates, including projected free cash flow of $437 million in 2024, and then extends these out over the next decade. By 2035, the model is using an extrapolated free cash flow figure of about $1.4b, with each year’s amount discounted back to reflect the time value of money.

Adding all those discounted cash flows together produces an estimated intrinsic value of about $209.00 per share. Compared with the recent share price of $62.13, this implies the stock is 70.3% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Halozyme Therapeutics is undervalued by 70.3%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Halozyme Therapeutics Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to connect what you pay per share with the earnings that support that price. It helps you see how many dollars you are paying for each dollar of current earnings, which is often a practical anchor when you are assessing an established business.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth potential and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually points to a lower one.

Halozyme Therapeutics currently trades on a P/E of 23.23x, compared with the Biotechs industry average of about 14.83x and a peer average of 19.77x. Simply Wall St’s Fair Ratio for Halozyme is 19.93x. This Fair Ratio is a proprietary metric that aims to capture what a suitable P/E might be after considering factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it adjusts for these elements, it can offer a more tailored reference point than a simple comparison with peers or the wider industry.

Comparing Halozyme’s actual P/E of 23.23x with the Fair Ratio of 19.93x suggests the shares trade at a higher level than this tailored benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Halozyme Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Halozyme Therapeutics together into a single story that ties what you think about ENHANZE, royalties, patents and competition to a clear forecast for revenue, earnings and margins. This is then translated into a Fair Value you can compare with the current price, all inside Simply Wall St’s Community page. Narratives update automatically when new news or earnings arrive. For example, one Halozyme Narrative might lean toward a higher fair value around US$91.0 based on stronger ENHANZE driven growth, while another might sit closer to US$51.0 with more weight on patent and pricing risks, giving you transparent scenarios to guide your own decisions.

For Halozyme Therapeutics however, we will make it really easy for you with previews of two leading Halozyme Therapeutics Narratives:

Fair value in this bullish narrative: US$84.50 per share

Implied discount to this fair value at the last close of US$62.13: about 26% undervalued

Analyst revenue growth assumption in this scenario: about 15.4% a year

• Royalty income from ENHANZE and newer biologic launches is expected to be a key earnings driver, supported by growing use of subcutaneous drug delivery.
• Analysts building this case are assuming higher profit margins over time, strong free cash flow and ongoing share buybacks to support earnings per share.
• The main watchpoints are regulatory changes, reliance on a handful of large partners, patent challenges and competition in drug delivery technologies.

Fair value in this bearish narrative: about US$59.56 per share

Implied premium to this fair value at the last close of US$62.13: about 4% overvalued

Analyst revenue growth assumption in this scenario: about 14.7% a year

• This case focuses on Halozyme’s dependence on ENHANZE, with concern that patent expiries, pricing pressure and rival drug delivery approaches could weigh on future royalties.
• Bearish analysts still model solid earnings and revenue growth, but assume the market eventually applies a lower P/E multiple to those earnings.
• They also highlight the risk that partners push for better economics or that new deals come with lower royalty rates, which could cap the long term value of the stock.

If you want to see how other investors are joining these pieces together into a full story, including detailed forecasts and valuation models, Curious how numbers become stories that shape markets? Explore Community Narratives.

Do you think there's more to the story for Halozyme Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.